LEADER 05128oam 2200565 450 001 9910822185203321 005 20190911100030.0 010 $a0-12-415911-7 035 $a(OCoLC)855906890 035 $a(MiFhGG)GVRL8CVU 035 $a(EXLCZ)992550000001111904 100 $a20131107d2013 uy 0 101 0 $aeng 135 $aurun|---uuuua 181 $ctxt 182 $cc 183 $acr 200 00$aNovel psychoactive substances $eclassification, pharmacology and toxicology /$fedited by Paul I. Dargan, David M. Wood 210 $aLondon $cAcademic Press$dc2013 210 1$aLondon :$cAcademic Press,$d2013. 215 $a1 online resource (xiv, 423 pages) $cillustrations (some color) 225 0 $aGale eBooks 300 $aDescription based upon print version of record. 311 $a0-12-415816-1 311 $a1-299-78230-2 320 $aIncludes bibliographical references and index. 327 $aFront Cover; Novel Psychoactive Substances: Classification, Pharmacology and Toxicology; Copyright Page; Contents; Forewords; List of Contributors; 1 Background; 1. Legal Classification of Novel Psychoactive Substances; Introduction; Historical Background; Legal Concerns; Chemical and Pharmacological Classification; Traditional Control Mechanisms; Specific Listing; Generic Definitions; The Analogue Approach; Recent Developments; Temporary Listing; New Zealand: Class D; UK: Importation Controls; Ireland: Criminal Justice (Psychoactive Substances) Act 2010; Japan: Non-authorised Pharmaceuticals 327 $aSwitzerland: Schedule 'e'Poland, Romania: Substitute Drugs; Finland: Intoxication and Harm; Medicines Legislation; Consumer Protection Legislation; International-level Initiatives; Other Control Options and Future Developments; References; 2. Monitoring Novel Psychoactive Substances; Introduction; Definitions; The Identification, Risk Assessment and Monitoring of Novel Psychoactive Substances; The EU Ews Information Exchange; Risk Assessment; Case Study: Mephedrone Risk Assessment; National European EWS Networks; The UK EWS; The French EWS; The Nordic Countries: Nordic-NADiS 327 $aInternational, Regional and National Drug Monitoring SystemsNational Drug Monitoring Systems; USA; Australia; New Zealand; South Africa; The United Nations System; World Health Organisation (WHO); United Nations Global SMART Programme; Inter-American Observatory on Drugs; Sources for Detecting and Monitoring Novel Psychoactive Substances; Forensic Science; Pill Testing; Wastewater Analysis and Pooled Urine Analysis; Computational Modelling; Hospital Emergencies Data; Internet Monitoring; Surveys and Studies on the Prevalence of Use of Novel Psychoactive Substances; Conclusions; References 327 $a3. Availability and Supply of Novel Psychoactive SubstancesBackground; Novel Psychoactive Substance Market; NPS Origins and Market Entry; NPS Market Structure; Supply Chain: Manufacturing and Distribution; Sale of NPS; Internet; Retail Vendors; Street Level Drug Dealers; Products; Pricing of NPS; Transaction Mechanisms; Marketing; Branding and Packaging; Misbranding; Market Dynamics; Conclusions; References; 4. Epidemiology of Use of Novel Psychoactive Substances; Introduction; General Population Surveys; Surveys in Young People; Adult Population Surveys 327 $aNon-probabilistic Convenience Sample SurveysMephedrone; Synthetic Cannabinoid Receptor Agonists; Salvia divinorum; Behavioural Epidemiology; Data from Medical Monitoring Systems; Alternative Methodologies to Assess Prevalence of NPS; Summary and Conclusions; References; 5. Social Issues in the Use of Novel Psychoactive Substances; Introduction; Availability; Prevalence in Context: Differentiated Demand in Different Leisure Venues; School and College Students; Bar Customers; Festival-goers; Dance Club Customers; Understanding Motivations: the Displacement Question 327 $aExploring Social Harms: Legislative Control and the Supply of Nps 330 $aNovel Psychoactive Substances: Classification, Pharmacology and Toxicology provides readers with background on the classification, detection, supply and availability of novel psychoactive substances, otherwise known as ""legal highs."" This book also covers individual classes of novel psychoactive substances that have recently emerged onto the recreational drug scene and provides an overview of the pharmacology of the substance followed by a discussion of the acute and chronic harm or toxicity associated with the substance. Written by international experts in the field, this multi-au 606 $aPsychotropic drugs 606 $aPsychopharmacology 606 $aSubstance abuse 606 $aNeuropharmacology 615 0$aPsychotropic drugs. 615 0$aPsychopharmacology. 615 0$aSubstance abuse. 615 0$aNeuropharmacology. 676 $a615.78 702 $aDargan$b Paul I. 702 $aWood$b David M. 801 0$bMiFhGG 801 1$bMiFhGG 906 $aBOOK 912 $a9910822185203321 996 $aNovel Psychoactive Substances$91757768 997 $aUNINA